Caitlin Cronin
Stock Analyst at Canaccord Genuity
(4.49)
# 311
Out of 4,711 analysts
18
Total ratings
64.29%
Success rate
20.47%
Average return
Main Sectors:
Stocks Rated by Caitlin Cronin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Buy | $60 | $56.50 | +6.19% | 2 | Nov 19, 2024 | |
| KRMD KORU Medical Systems | Maintains: Buy | $3 → $4 | $4.02 | -0.50% | 2 | Nov 14, 2024 | |
| TELA TELA Bio | Maintains: Buy | $12 | $2.85 | +321.05% | 3 | Oct 4, 2024 | |
| ATEC Alphatec Holdings | Maintains: Buy | $20 | $9.35 | +113.90% | 3 | Aug 30, 2024 | |
| INMD InMode | Maintains: Hold | $21 → $16 | $17.08 | -6.32% | 2 | Jul 12, 2024 | |
| AXGN Axogen | Reiterates: Buy | $15 | $15.64 | -4.09% | 2 | Jun 20, 2024 | |
| ZBH Zimmer Biomet Holdings | Reiterates: Hold | $130 | $107.12 | +21.36% | 1 | Feb 23, 2024 | |
| ENOV Enovis | Maintains: Buy | $73 → $75 | $43.12 | +73.93% | 1 | Feb 23, 2024 | |
| GMED Globus Medical | Reiterates: Buy | $79 | $82.63 | -4.39% | 1 | Feb 21, 2024 | |
| RBOT Vicarious Surgical | Downgrades: Hold | $270 → $12 | $12.00 | - | 1 | Nov 14, 2023 |
Vericel
Nov 19, 2024
Maintains: Buy
Price Target: $60
Current: $56.50
Upside: +6.19%
KORU Medical Systems
Nov 14, 2024
Maintains: Buy
Price Target: $3 → $4
Current: $4.02
Upside: -0.50%
TELA Bio
Oct 4, 2024
Maintains: Buy
Price Target: $12
Current: $2.85
Upside: +321.05%
Alphatec Holdings
Aug 30, 2024
Maintains: Buy
Price Target: $20
Current: $9.35
Upside: +113.90%
InMode
Jul 12, 2024
Maintains: Hold
Price Target: $21 → $16
Current: $17.08
Upside: -6.32%
Axogen
Jun 20, 2024
Reiterates: Buy
Price Target: $15
Current: $15.64
Upside: -4.09%
Zimmer Biomet Holdings
Feb 23, 2024
Reiterates: Hold
Price Target: $130
Current: $107.12
Upside: +21.36%
Enovis
Feb 23, 2024
Maintains: Buy
Price Target: $73 → $75
Current: $43.12
Upside: +73.93%
Globus Medical
Feb 21, 2024
Reiterates: Buy
Price Target: $79
Current: $82.63
Upside: -4.39%
Vicarious Surgical
Nov 14, 2023
Downgrades: Hold
Price Target: $270 → $12
Current: $12.00
Upside: -